Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020069292 - MÉTHODE DE PRÉVENTION ET DE TRAITEMENT DE L'INFLAMMATION ET DE LA FIBROSE PULMONAIRE

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

What is claimed is:

1. A method of treating, reducing the risk of, preventing, or alleviating a pulmonary disease or condition in a subject, comprising administering to the subject a therapeutically effective amount of a cerium oxide nanoparticle (CNP).

2. The method of claim 1, wherein the CNP comprises a therapeutic agent.

3. The method of claims 1 or 2, wherein the therapeutic agent is an anti-inflammatory agent.

4. The method of claims 1 or 2, wherein the therapeutic agent is a micro-RNA (miRNA).

5. The method of any one of claims 1-4, wherein the miRNA is miRNA-l46a.

6. The method of claims 4 or 5, wherein the miRNA is covalently attached to the CNP.

7. The method of claim 4 or 5, wherein the miRNA is non-covalently associated with the CNP.

8. The method of any one of claims 1-7, wherein the pulmonary disease or condition is selected from pulmonary inflammation, pulmonary fibrosis, obstructive pulmonary disease (COPD), emphysema, asthma, idiopathic pulmonary fibrosis, pneumonia, tuberculosis, cystic fibrosis, bronchitis, pulmonary hypertension (e.g., Idiopathic Pulmonary Arterial Hypertension (IPAH), interstitial lung disease, and lung cancer.

9. The method of claim 8, wherein the pulmonary disease or condition is selected from

pulmonary inflammation, pulmonary fibrosis, COPD, emphysema, asthma, pulmonary fibrosis, and cystic fibrosis.

10. The method of any one of claims 1-7, wherein the pulmonary disease or condition is caused by inflammation, autoimmune disease, scleroderma, rheumatoid arthritis, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), pulmonary embolism, congestive heart failure, heart valve disease, extended periods of low oxygen levels in the blood, medication, or substance of abuse.

11. The method of claim 10, wherein the pulmonary disease or condition is caused by

inflammation.

12. A method of reducing or suppressing inflammation in the lung in a subject, comprising administering to the lungs of a subject in need thereof a therapeutically effective amount of a CNP linked to miRNA-l46a.

13. A method of promoting lung repair in a subject, comprising administering to the lungs of a subject in need thereof a therapeutically effective amount of a CNP linked to miRNA-l46a.

14. The method of any one of claims 1-13, wherein the subject is a human.

15. The method of any one of claims 1-14, wherein the CNP is administered by inhalation.

16. The method of any one of claims 1-15, wherein the CNP is administered as an aerosol

formulation.

17. The method of any one of claims 1-15, wherein the CNP is administered as a metered dose inhaler.

18. The method of any one of claims 1-15, wherein the CNP is administered from a nebulizer.

19. The method of any one of claims 1-15, wherein the CNP is administered as a dry powder composition for topical delivery to the lung by inhalation.

20. The method of any one of claims 1-15, wherein the CNP is administered from a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), or a metered dose inhaler (MDI).

21. The method of any one of claims 1-15, wherein the CNP is administered to nasal passages of the subject from a pre-compression pump.

22. The method of any one of claims 1-15, wherein the CNP is administered as an intranasal spray.